{"title":"一种治疗银屑病的新方法：光敏A3腺苷受体活化。","authors":"Federica Cherchi, Elisabetta Coppi","doi":"10.1007/s11302-025-10079-6","DOIUrl":null,"url":null,"abstract":"<p><p>This Journal Club article discusses a recent study by López-Cano and collaborators, published in Journal of the American Chemical Society (López-Cano et al. Pharmacol Res 170:105731, 2021), which introduces a pioneering therapeutic approach for psoriasis based on systemic administration of a photoswitchable adenosine A<sub>3</sub> receptor (A<sub>3</sub>R) agonist, MRS7787, to counteract psoriasis-relate skin alterations by topic exposure to light. The study presents a synthesis strategy, photochemical characterization, and functional evaluation of the compound, which provides light-controlled relief from IL-23-induced psoriatic skin lesions in the mouse ear, a corroborated animal model of psoriasis. The innovation offers insights into localized, time-specific, and reversible modulation of G protein-coupled receptor (GPCR) activity and has implications for drug discovery and optopharmacology, highlighting their potential for new strategies in treating skin-related diseases.</p>","PeriodicalId":20952,"journal":{"name":"Purinergic Signalling","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A new approach to psoriasis therapy: photoswitchable A<sub>3</sub> adenosine receptor activation.\",\"authors\":\"Federica Cherchi, Elisabetta Coppi\",\"doi\":\"10.1007/s11302-025-10079-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This Journal Club article discusses a recent study by López-Cano and collaborators, published in Journal of the American Chemical Society (López-Cano et al. Pharmacol Res 170:105731, 2021), which introduces a pioneering therapeutic approach for psoriasis based on systemic administration of a photoswitchable adenosine A<sub>3</sub> receptor (A<sub>3</sub>R) agonist, MRS7787, to counteract psoriasis-relate skin alterations by topic exposure to light. The study presents a synthesis strategy, photochemical characterization, and functional evaluation of the compound, which provides light-controlled relief from IL-23-induced psoriatic skin lesions in the mouse ear, a corroborated animal model of psoriasis. The innovation offers insights into localized, time-specific, and reversible modulation of G protein-coupled receptor (GPCR) activity and has implications for drug discovery and optopharmacology, highlighting their potential for new strategies in treating skin-related diseases.</p>\",\"PeriodicalId\":20952,\"journal\":{\"name\":\"Purinergic Signalling\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Purinergic Signalling\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11302-025-10079-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Purinergic Signalling","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11302-025-10079-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
这篇杂志俱乐部的文章讨论了López-Cano和合作者最近发表在《美国化学学会杂志》（López-Cano等）上的一项研究。Pharmacol Res 170:105731, 2021)，该研究介绍了一种开创性的银屑病治疗方法，该方法基于全身给药光切换腺苷A3受体（A3R）激动剂MRS7787，以抵消银屑病相关的皮肤变化。本研究介绍了该化合物的合成策略、光化学表征和功能评价，该化合物可光控缓解il -23诱导的银屑病小鼠耳损伤，这是一种确证的银屑病动物模型。这项创新提供了对G蛋白偶联受体（GPCR）活性的局部、时间特异性和可逆调节的见解，并对药物发现和光学药理学具有重要意义，突出了它们在治疗皮肤相关疾病的新策略方面的潜力。
A new approach to psoriasis therapy: photoswitchable A3 adenosine receptor activation.
This Journal Club article discusses a recent study by López-Cano and collaborators, published in Journal of the American Chemical Society (López-Cano et al. Pharmacol Res 170:105731, 2021), which introduces a pioneering therapeutic approach for psoriasis based on systemic administration of a photoswitchable adenosine A3 receptor (A3R) agonist, MRS7787, to counteract psoriasis-relate skin alterations by topic exposure to light. The study presents a synthesis strategy, photochemical characterization, and functional evaluation of the compound, which provides light-controlled relief from IL-23-induced psoriatic skin lesions in the mouse ear, a corroborated animal model of psoriasis. The innovation offers insights into localized, time-specific, and reversible modulation of G protein-coupled receptor (GPCR) activity and has implications for drug discovery and optopharmacology, highlighting their potential for new strategies in treating skin-related diseases.
期刊介绍：
Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
